If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 18

An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses

Objective
IIT-GEORGE-I-PREDICT
Protocol No
IIT-GEORGE-I-PREDICT
Categories
Cancer, Colorectal, Gynecologic Cancers, Esophagus, Other Urologic, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Esophagus, Skin Cancers, Stomach, Prostate and Urologic Cancers, Pancreas/Liver, Breast Cancers, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Lung, Thoracic Cancers

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer, Kidney, Skin Cancers, Stomach, Uterine, Lung, Other Urologic, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Prostate and Urologic Cancers, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab or Ifinatamab Deruxtecan (I-DXd) in Patients with Advanced Cancers Asso

Objective
Phase 1/2 open-label, multicenter study to evaluate the safety, PK, and pharmacodynamics of HPN328 in patients with SCLC or with advanced solid tumors associated with expression of DLL3. This study will be divided into 2 parts: Dose Escalation (Part 1) and Expansion (Part 2).
Protocol No
HARPOON-HPN328-4001
Categories
Cancer, Lung, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers

REMASTer: REcurrent Brain Metastases After SRS Trial

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers